Key facts
- It has raised $14.0M; the latest was Later Stage VC ($14.0M) in Nov 2025.
- Notable investors include Qiming Venture Partners, Tailong VC, Taikun Fund, Jiangsu Winfast Investment, Jiaxing Deshi Private Equity Fund Management — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Yangli Pharmaceutical
- ·The full record, as it builds
Funding rounds
No funding rounds for Yangli Pharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Yangli Pharmaceutical
Developer of innovative drug research technology designed to develop therapies for cancer and chronic illnesses. The company offers proprietary compounds, fast-tracked clinical development, and independent R&D capabilities, enabling pharmaceutical partners and healthcare providers to deliver novel treatments with enhanced efficiency and reduced reliance on imports.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2018
- Website
- yanglics.zhulu76.com/
- Ownership
- Privately Held (backing)
Yangli Pharmaceutical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Yangli Pharmaceutical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Yangli Pharmaceutical in its N-PORT filings yet. We sweep new filings monthly.